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SUMMARY
A Register of HIV-infected persons who have had a negative antibody test within 3 years of
their first antibody positive test (seroconverters) is being set up in the UK to monitor the
distribution of times from HIV seroconversion to AIDS (the incubation period) and to death.
It will also provide a national resource for use by those designing studies in this group of
individuals. Clinicians caring for HIV-positive persons in Genito-Urinary Medicine, Infectious
Disease and other departments throughout the UK were asked to participate by providing
information on eligible subjects. Most laboratories undertaking HIV antibody testing were also
contacted and asked to provide the name of the attending clinician for all seroconverters
identified through the HIV laboratory reporting systems of the PHLS Communicable Disease
Surveillance Centre (CDSC) and the Scottish Centre for Infection and Environmental Health
(SCIEH) and for any other seroconverters known to them but not identified by CDSC or
SCIEH. Data items sought for the Register include: sex, ethnic group, probable route of HIV
transmission, annual CD4 counts, details of therapy and prophylaxis prescribed, AIDS-defining
events and vital status. Follow up information is collected annually. Wherever possible, all
seroconverters known to a clinic have been identified, whether currently alive or dead, either
from clinic records or laboratory reporting or both. The objective is to establish and update a
complete register of seroconverters on a long-term basis to provide reliable estimates of the
incubation period on which future projections of AIDS cases in the UK can be made.
BACKGROUND AND OBJECTIVES
Knowledge of the distribution of intervals from
human immunodeficiency virus (HIV) infection to the
development of acquired immunodeficiency syndrome
(AIDS) and to death, and the factors affecting these
intervals is vital for an understanding of the natural
history of HIV infection and for making projections
of future numbers of AIDS cases. These distributions
have changed since the beginning of the epidemic due
particularly to the introduction of anti-retroviral
treatment and prophylaxis for Pneumocystis carinii
pneumonia and other opportunistic infections [1,2].
It is likely that new advances in the management of
individuals with HIV infection will influence these
distributions. Further, changes in the incubation
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period distribution could occur even in the absence of
changes in available treatments and treatment uptake,
due to the evolving distributions of new viral strains in
HIV-infected persons [3, 4]. It is therefore important
to monitor whether there are changes in the in-
cubation period distribution and, if so, the extent of
those changes and factors associated with them.
A number of studies have provided estimates for
these incubation periods in different population
groups [5-22]. Most studies have tended to focus on
one transmission category, e.g. homosexual men,
injecting drug users, or haemophiliacs, are small in
size, or are no longer recruiting new subjects.
A Register of HIV-infected individuals in whom the
date of seroconversion is known with reasonable
precision (seroconverters) is currently being set up in
the UK to monitor changes in the distribution of
intervals from seroconversion to onset of AIDS, using
the 1993 European case definition [23] (referred to as
'the incubation period') and death. Seroconversion is
estimated as the mid-point between the last negative
and first HIV positive antibody test dates, and is used
to approximate the time of infection with HIV. The
Register will also provide information on factors
associated with the length of these intervals. It is
intended to be complete and ongoing to provide
constant and regular monitoring of these periods. The
Register will be a shared national resource for use by
those designing studies to help improve understanding
of HIV pathogenesis and of immunological and
virological markers of infection and their relation to
prognosis.
METHODS
Definition of a seroconverter
For the purposes of the Register, a seroconverter is
defined as an HIV-seropositive person aged 16 years
or over on whom an HIV antibody test was performed
and found to be negative no more than 3 years prior
to the first positive antibody test. In the absence of a
negative result, persons identified during the acute
infection stage, namely when infection has occurred
but before full seroconversion, will also be included in
the study. Laboratory evidence for this acute infection
is required, the details of which were reached by
consensus among expert virologists at the request of
the Steering Committee (see Appendix). The Register
is not actively recruiting haemophiliac patients be-
cause they are followed up by the UK Haemophilia
Centre Directors' HIV Working Party.
A maximum period of 3 years between the negative
and positive tests was chosen, but additional analyses
using a narrower period will also be undertaken as
appropriate. Too narrow a period would inevitably
result in the selection of a group of individuals
undergoing HIV testing at very frequent intervals.
Identifying study subjects
Clinicians in the UK have reported AIDS cases to the
Public Health Laboratory Service AIDS Centre at the
Communicable Disease Surveillance Centre (CDSC)
and the Scottish Centre for Infection and Environ-
mental Health (SCIEH) since 1982 on a voluntary and
confidential basis. Laboratory reporting to CDSC
and SCIEH of newly-identified HIV infection began
in the latter part of 1984. AIDS case reporting is
estimated to be 87% complete while the HIV
laboratory reporting is estimated to cover around
80% of known infections [24,25]. Clinical and
laboratory reporting run independently but the use of
a soundex code (a code derived from the patient's
surname comprising of a letter followed by three
digits) as well as the date of birth allow both the link
between an HIV and an AIDS case report on the same
individual to be made, and the elimination of possible
duplicates on either system.
Clinical centres
Clinicians from Genito-Urinary Medicine, Infectious
Disease and other specialities from centres in the UK
taking part in the Medical Research Council (MRC)
clinical trials in HIV infection were invited to
participate by providing information on patients who
meet the definition of a seroconverter. Additionally,
clinicians from centres not taking part in the MRC
trials but whose centre has reported a total of 10 or
more AIDS cases to CDSC or to SCIEH were also
invited to participate.
Laboratories
Laboratory directors and medical microbiologists
were also contacted by letter and telephone and asked
to participate by helping to identify eligible subjects.
These include National Health Service, Public Health
and private laboratories, as well as regional Blood
Transfusion Centres.
In October 1986 the PHLS Collaborative Lab-
oratory Study on HIV infection (the 'Denominator
Study') was initiated to gather information on all HIVUK Register of HIV Seroconverters 307
testing and therefore identify repeat tests on the same
individual and hence incident infections. It comprised
nine laboratories and expanded to include 18 labora-
tories by the end of 1989. As participating laboratories
record all HIV tests, both negative and positive, the
identification of seroconverters at these laboratories
was made much simpler. A similar surveillance
mechanism was set up in November 1988 in Scotland
through which all laboratories performing HIV testing
report centrally to SCIEH. Colleagues at SCIEH have
also undertaken follow up, through the Blood
Transfusion Service, of HIV seropositive donors with
previous HIV negative donations.
Detection of duplicate reports
The current CDSC HIV laboratory reporting form,
which has been in use since March 1993, contains a
specific question asking whether a negative result had
previously been obtained. For all reports where this
item of information was provided, the reporting
laboratory was contacted and asked for the name and
address of the clinician looking after the patient, or, if
this was not known, the name and address of the
clinician requesting the HIV test. The clinician was
then asked to register the patient by completing a
registration form and also to identify and register all
other seroconverters from their centre including those
known to be dead, transferred to other centres, or lost
to follow-up. Duplicate reports made by the clinic and
the laboratory on the same individual were identified
by using soundex code and date of birth matching.
Prior to March 1993, there was no specific question
regarding a previous negative test on the CDSC form.
All laboratories who have reported new HIV infec-
tions first diagnosed by them since January 1990 were
also asked to check for any previous negative results
for all individuals with a positive result between
January 1990 and March 1993 who were not already
known to have had a previous negative result.
Retrospective ascertainment
A number of laboratories and clinical centres, par-
ticularly those with large case loads of HIV-infected
persons, include information on previous negative
results on their patient databases. In order to identify
subjects eligible for the Register retrospectively,
information is sought, wherever possible, from the
local laboratory performing HIV testing. This method
is least likely to result in biased estimates of the
incubation period distribution as it is independent of
the patient's vital status and attendance at a clinic. As
this is not always possible, information from the
clinic is also used; this may give biased estimates
towards survivors if they include only current atten-
ders, but seroconverters with a negative test performed
at another laboratory can also be identified. Com-
puterized records from the clinic are used whenever
available, but in order to identify eligible subjects who
had died or transferred to other centres before the
computerization of records had taken place the search
is supplemented by case note review where feasible.
By close contact with centres and laboratories we
aim to identify and minimize potential biases in the
incubation period estimate (discussed below), which
are due to the method of recruitment of eligible cases,
by seeking information on the completeness of the
local records, either electronic or manual, in particular
the inclusion of patients no longer attending the
centre or who had died.
Clinicians are also asked, with informed and
written consent from the patient, to take a blood
sample for central serum storage. Ethics committee
approval was obtained for this from all participating
clinical centres.
Information collected
The following information is collected for all sero-
converters either by asking the clinician or research
nurse to complete a form or by extraction from the
clinic database: Soundex code, initials, date of birth,
clinic/hospital number, sex, ethnic group, probable
route of virus transmission, likely country of infection,
presence of a seroconversion illness (with date and
main symptoms), dates of last negative and first HIV
positive antibody tests and where these were per-
formed, vital status and, if dead, date of death.
The following data are also collected initially and
on an annual basis: CD4 cell counts, details of
antiretroviral therapy and prophylaxis for oppor-
tunistic infections (either as open label therapy or as
part of a clinical trial), AIDS-defining events, vital
status and, if dead, date and likely cause(s).
Information about the nature and completeness of
any existing local databases was sought from the
major centres caring for HIV infected individuals. On
the basis of this, the study registration and follow up
forms were designed to be compatible with the
information collected routinely. This was of particular
relevance to information on drugs prescribed. At
registration, only information on the date of start of308 UKRHS Steering Committee
Table 1. Characteristics of seroconverters reported to the Register: October 1994-February 1996
Number of reports
(n = 1348)
Proportion of cases
Sex
Exposure category
Seroconversion
interval
Age at first antibody
positive test (yrs)
Male
Female
Sex between men*
Sex between men and
women
Injecting drug use
Other/undeterminedf
1 calendar month
1-12 months
13-24 months
25-36 months
Median (range)
1203
145
1040
134
146
28
57
688
382
221
28(15-64)
89
11
77
10
11
2
4
51
28
16
* Includes 22 men who also reported to have injected drugs.
t The Register is not actively recruiting haemophiliacs as they are already followed up by the UK Haemophilia Centre
Directors' HIV Working Party.
each drug prescribed is requested. Strict confi-
dentiality is maintained. No names or addresses of
seroconverters are requested. The database for the
study is held within a secure building with separate
coded access and data are completely inaccessible
except through the use of passwords known to key
individuals only. Data released to other researchers,
which would require the approval of the Steering
Committee, would contain no information that could
lead to the identification of seroconverters.
Follow up information
Follow up data is collected on an annual basis
through the appropriate clinical centre. Only in-
formation on whether the patient is currently taking
the drug or any additional drugs prescribed or any
stopped in the interval since last follow up will be
sought. Any temporary changes in medication in the
intervening period will not be recorded as details are
unlikely to be available. It is unlikely that this level of
detail would have a substantial impact on the analyses.
The AIDS databases both at CDSC and SCIEH will
also be used to identify AIDS cases and deaths
occurring in patients who have stopped attending
their clinic.
The Office of Population Censuses and Surveys
(OPCS) in England and Wales and the General
Register Office (GRO) in Scotland are the central
registries for birth, marriage, and death. It is expected
that they will provide information annually on deaths
not known to CDSC or SCIEH by matching records
of deaths in the UK against those of all patients lost
to follow up on the Register based on Soundex code,
date of birth and sex. As no names will be disclosed to
the Register by OPCS or GRO, once a possible match
or a number of probable matches are made they will
be verified with the collaboration of the clinician last
known to have provided patient care. In this manner
the HIV status of persons on the Register will not
become disclosed to either OPCS or GRO.
RESULTS
By the end of February 1996, 142 clinical centres and
136 laboratories had been contacted, of which 131
(92%) and 103 (76%), respectively, have agreed to
participate, representing 91% of AIDS case reports
and 97 % of HIV infection reports in the UK to date.
A total of 2070 HIV antibody positive persons aged 16
years or more who were not known to be haemophiliac
patients and had had a previous negative antibody
test were identified from all sources. Full information
has been received on 1526 individuals, 806 of whom
appear not to be known to either CDSC or SCIEH.
The remaining 544 are known to the CDSC HIV
laboratory reporting system and to SCIEH and, as
clinical information has not yet been received, are not
included on the Register.
Of the 1526 seroconverters reported to the Register,
987 (65%) were reported from 13 centres in London,
219 (14%) from 12 centres in Scotland, and 320
(21 %) from 52 centres in the rest of the UK. Of these,
1120 were identified through clinic records, 295UK Register of HIV Seroconverters 309
Table 2. Year of estimated seroconversion* for cases
reported October 1994-February 1996
Year
Number of
cases
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
31
49
40
55
58
86
114
155
168
203
214
134
40
1
* Mid-point between the first positive and last negative
HIV antibody tests.
NB. not all individuals will contribute information to
estimates of the incubation period from this point (see
Discussion - Statistical issues and possible biases).
through laboratory records, and 111 through both the
clinic and laboratory. The seroconversion interval, i.e.
the time difference between a first antibody positive
and last antibody negative tests for HIV, is within one
calendar month for 57 reports, 1-12 months for 688
reports, 13-24 months for 382 reports, 25-36 months
for 221 reports and over 36 months for 153 reports.
For 25 reports no date was given for either the
positive or negative tests or both.
The characteristics of the 1348 reports with a
seroconversion interval of 3 years or less are outlined
in Table 1. Most (77%) were infected through sex
between men, 10% through sex between men and
women, and 11 % through injecting drug use. This
contrasts with 65%, 19% and 12%, respectively,
among reported cases of HIV infection in the UK [26].
Most seroconversions are estimated to have taken
place in 1992 and 1993 but information is available on
persons believed to have seroconverted since 1983
(Table 2).
DISCUSSION
Statistical issues and possible biases
The incubation period distribution, given by the
cumulative probability of developing AIDS within t
years of infection will be estimated using Kaplan-
Meier estimation. Attempts will also be made to fit
various parametric models such as Weibull or Gamma
distributions. The effects of variables on the length of
survival will be examined using, principally, Cox
proportional hazard models.
The aim is to include all seroconverters known to
clinics and laboratories on the Register including
patients alive at the time the Register is set up and all
patients who have died. However, serious bias may
arise if the likelihood of a person being included on
the Register is dependent on how rapidly that
individual develops AIDS and/or dies. For example,
in some centres seroconverters who have progressed
rapidly and died may be less likely to be registered
than those who are currently attending. This problem
arises when a clinic/laboratory does not have a
complete record of all patients ever seen. In such
centres data on, for example, a person who sero-
converted in 1987, and is registered in 1995, cannot be
used to derive information on the first 8 years of the
incubation period since, if the patient had died within
8 years (i.e. before 1995), they may well have not been
included on the Register. Such a patient can thus only
be entered in the 'risk set' for the analysis in 1995 at
8 years. This is referred to as 'late entry'. If such a
patient had attended at a clinic or was identified
through a laboratory with complete records of every
patient seen/tested since, for example 1990, they can
be entered into the risk set at 3 years from sero-
conversion (1990-1987 = 3 years) since survival or
death after this date will not have influenced whether
they are included on the Register.
For individuals from centres whose ascertainment
is believed to be complete from laboratory and/or
clinic records (that is, all patients alive, dead,
transferred and lost to follow up are included), follow
up through the Register commences from each
individual's seroconversion time. However, for centres
where ascertainment is judged to be complete only
from a given date, h, seroconverters are treated as
' late entry' subjects and each enters the ' risk set' at (h
- estimated date of seroconversion). If ascertainment
from a centre is not complete from any point in time,
follow up for all seroconverters from that centre will
commence from the date of entry to the Register.
Follow up (i.e. entry into the 'risk set') for subjects
already known to be HIV infected when transferring
into a centre commences from the date they first
attended the clinic with complete records on all
patients. If this is uncertain, or if neither clinic have
complete records the follow up of such subjects
commences from date of entry to the Register.310 UKRHS Steering Committee
Table 3. Number of patients recruited from each of 3 hypothetical clinics
Clinic
A
B
C
Estimated year
1984
20*
0
25
1985
10
25
25
of seroconversion
1986
0
0
0
1987
20
0
25
1988
0
0
0*
1989
25
25
0
1990
0
0*
0
1991
0
0
0
1992
20
25
25
1993
0
0
0
1994
5
25
0
Total
recruited
100
100
100
* Time h from which records are believed to be complete. Patient numbers to the left of these are treated as 'late entry'
subjects in the analysis.
Table 4. Life table of retrospectively identified seroconverters
Time from
seroconversion
(yrs) Numbers of patients in risk set Number of events
10
10
15
6
10
12
7
10
14
13
Cumulative
event-free
survival
probability
0-94
0-90
0-83
0-81
0-78
0-74
0-72
0-69
0-64
0-60
0
1
2
3
4
5
6
7
8
9
175*
205
190 + 25J
209 + 25J
224 + 25f
237
230
220
206
* 100 patients from clinic A, 50 from clinic B, and 25 from clinic C.
t Late entry subjects from clinic B.
Late entry subjects from clinic C.
To give examples of this potential bias, consider the
following scenarios (Table 3):
(i) In clinic A, it is possible to identify all HIV
infected persons who have ever attended the clinic
regardless of whether they have since died, transferred
to other centres or are currently alive and attending at
this clinic.
(ii) In clinic B, records became computerized for
patients attending from January 1990 onwards.
Therefore, eligible subjects who had died or trans-
ferred to other centres prior to January 1990 were not
entered onto the system and cannot, therefore, be
identified.
(iii) In clinic C, complete records for attenders are
available from January 1988, and so patients who had
died or transferred to other centres prior to that date
are not included.
For patients in clinic A follow up can be backdated
to the date of their individual HIV positive tests and
their date of entering the risk set is, therefore, the
estimated seroconversion date.
For patients in clinic B follow up can only start
from January 1990 since information is incomplete for
the period prior to this date and their follow up
commences from that point so that they enter the risk
set at the number of years after seroconversion they
were in 1990. Similarly, patients registered from clinic
C enter the risk set at the number of years after
seroconversion they were in 1988 and their follow up
begins from that point. To illustrate how the problem
of 'late entry' is dealt with, let us suppose that 100
eligible seroconverters are identified from each of the
three centres A, B and C and their estimated dates of
HIV seroconversion are as illustrated in Table 3. The
resulting lifetable for analysis would resemble Table 4.
A bias concerning the representativeness of sero-
converters on the Register may arise because persons
who undergo repeat testing for HIV are not likely to
be truly representative of all HIV infected persons.
For example, heterosexuals acquiring the virus
through sexual contact often have not previously
perceived themselves to be at risk of HIV infectionUK Register of HIV Seroconverters 311
and so tend not to have had previous negative tests for
HIV and, therefore, are under-represented among
seroconverters.
Future developments
As persons with a previous negative antibody test are
likely to remain a small proportion of all HIV-infected
individuals, international collaboration is important
in order to pool information and increase the degree
of confidence in estimates of the incubation period,
not only for homosexual and bisexual men but also
for heterosexual men and women. This is of crucial
importance for making reliable estimates of current
and future AIDS case load and recent HIV prevalence
[24, 25].
Due to the relatively low incidence of HIV infection,
incident cohorts, i.e. cohorts of initially HIV sero-
negative persons followed up through seroconversion
to AIDS and death, require many years of follow up.
A number of studies on the incubation period
overcome this problem by using information from
prevalent cohorts [6,8,11,12,27,28], i.e. persons
already known to be HIV seropositive when recruited.
As subjects in prevalent cohorts are by definition
already HIV infected, the unobserved period of their
HIV infection has to be accounted for and supple-
mented with information from other sources. The UK
Register of HIV Seroconverters aims to include all
seroconverters, to identify all potential biases and to
account for them in the analysis. This will ensure that
the Register is as close as possible to a cohort of
individuals with incident HIV infection.
Response from laboratories and clinical centres in
the UK has been encouraging. Much of the effort in
identifying eligible subjects is concerned with retro-
spective identification and ascertainment of the com-
pleteness of the records in individual clinical centres.
The mechanism for identifying seroconverters pro-
spectively is unlikely to require as much effort.
APPENDIX
Definition of 'acute infection'
(a) An individual believed to be at increased risk for
HIV infection presenting with an illness compatible
with acute primary HIV infection without docu-
mentation of a negative HIV antibody test will be
enrolled into the study pending the outcome of
laboratory investigations to establish evidence of
recently acquired infection, as detailed below. When
the results of the investigations are available, indi-
viduals not meeting these criteria will be removed
from the Register.
(b) Any other HIV positive individual without a
previous negative test in whom the laboratory criteria
below have been met will be enrolled.
Laboratory criteria of recent seroconversion (one
criterion required)
(a) The presence of p24 antigen, confirmed by
neutralization, and/or PCR positivity, in the absence
of total anti-HIV at that time, but in whom anti-HIV
is demonstrated in a specimen collected within 6
months.
(b) Weak reactivity in EIA or low titre (< 256) by
Serodia-HIV and IgM anti-HIV or p24 antigen and
seroconversion-type Western Blot pattern, with
either:
- increasing titres of anti-HIV/EIA reactivity in speci-
mens collected within a 3-month period but tested
simultaneously, or
- development of new bands or intensification of
weakly reactive bands in two or more sequential
sera collected at an interval of no more than 3
months and tested contemporaneously by Western
Blot.
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